Contact Anand S. Patel, MD
Title CEO


ChemoFilter is developing a novel catheter device enables chemotherapy delivery in a targeted manner, reducing patient side effects and improving treatment efficacy. The ChemoFilter device filters chemotherapeutics from the bloodstream, preventing toxic drugs from leaving the tumor site.
ChemoFilter’s first version will treat unresectable liver cancer, the 3rd leading cause of cancer death with over 600,000 new cases per year by working in tandem with trans-arterial chemoembolization (TACE), the current standard of care for this disease. ChemoFilter will save the healthcare system over $5,000 per patient, while increasing hospital and physician margins and improving patient care. ChemoFilter has potential worldwide sales of over $1 billion in liver cancer with the opportunity to expand into other cancers.
A UCSF based startup, ChemoFilter is supported by seed grants from UCSF, Society of Interventional Radiology, and the prestigious NIH Small Business Technology Transfer (STTR) grant.